Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AMA MULTIVITAMIN PARENTERAL GUIDELINES SHOULD BE MODIFIED

Executive Summary

AMA MULTIVITAMIN PARENTERAL GUIDELINES SHOULD BE MODIFIED to require higher doses of vitamins B1, B6 C and folate in the adult preparations, a joint American Medical Association (AMA)/FDA panel concluded Aug. 21. The panel met to reassess the AMA's guidelines for multivitamin preparations for parenteral use, published in 1975 and adopted by FDA in 1979, in light of the results of studies by USV, Roche and Abbott. FDA had approved the firms' multivitamin preparations with the understanding that postmarketing studies would be conducted to test the dose that was recommended by the AMA. Upon reviewing the three firms' studies and other currently available information, the panel concluded that the guidelines should be revised to raise, for adults, the amounts of folate from 400 ug to 600 ug, vitamin B1 from 3 mg to 6 mg, vitamin B6 from 4 mg to 6 mg, and vitamin C from 100 mg to 200 mg. Studies indicated, the panel agreed, that adults on Total Parenteral Nutrition (TPN) formulated according to the 1975 guidelines were in the "low normal range" for those four vitamins. The panel also agreed to consider adding, at a later time, vitamin K to the suggested composition for adult I.V. multivitamin formulations. The possible addition of vitamin K to the formulation guidelines will be discussed at a later meeting when more information on possible problems and recommmended dose is available, the panel concluded. Citing the varied testing procedures of vitamin availability in TPN patients, the panel recommended that FDA outline uniform procedures for I.V. multivitamin protocols. Panel member Maurice Shils, MD, Memorial Sloan-Kettering Cancer Center, suggested that with regard to future studies there should be "standardization of the total amount of time on the test dose, standardization on the duration of infusion, standardization of the time of adding the vitamins to the infusion ]and[ standardization of the time of sampling after termination of infusion of vitamins." The panel agreed that the specifics of the protocols would have to be decided at a future meeting. With regard to the suggested composition of the pediatric formulation, the panel agreed that there is no evidence to warrant a change from the 1975 guidelines. However, the panel agreed with a recommendation by Harry Greene, MD, Vanderbilt University Medical Center, to "convene a special group of interested parties to review the data that is available for premature infants and to make recommendations based on current knowledge about the needs and requirements of this special group of infants as far as vitamin and nutrient intakes."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel